Female Sexual Pain Disorders : (Record no. 20383)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11175nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6317475 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724114501.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781119482611 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781119482666 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6317475 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6317475 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1193126965 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC560.D97 .F463 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 618.1/7 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Goldstein, Andrew T. |
| 245 10 - TITLE STATEMENT | |
| Title | Female Sexual Pain Disorders : |
| Remainder of title | Evaluation and Management. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 2nd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2019. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (467 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Chapter 1 Nosology of Pelvic Pain and Vulvodynia -- 1.1 Introduction -- 1.2 Chronic Pelvic Pain Nosology -- 1.3 Bladder Pain Syndrome -- 1.4 Nosology of Sexual Pain -- 1.4.1 Genetic Factors -- 1.4.2 Hormonal Factors -- 1.4.3 Inflammation -- 1.4.4 Musculoskeletal -- 1.4.5 Neurological Mechanisms -- 1.4.6 Psychosocial Factors -- 1.4.7 Embryological/Congenital Factors -- 1.4.8 Associated Factors: Conclusion -- 1.5 Other Definitions of Vulvar Pain -- 1.6 Conclusion -- References -- Chapter 2 The Prevalence and Relevance of Vulvodynia -- 2.1 Introduction -- 2.2 Prevalence -- 2.3 Comorbid Conditions -- 2.4 Relevance to the Individual Woman, Family, and Society -- 2.5 Multidisciplinary Treatment -- 2.6 Recommendations -- 2.7 Conclusion -- References -- Chapter 3 Pathophysiology of Pain: Peripheral and Central -- 3.1 Introduction -- 3.2 Nociception or Pain? -- 3.3 Basics of Nociception -- 3.4 Hormone Regulation -- 3.5 Somatic and Visceral Pain -- 3.6 Referred Pain -- 3.7 Inflammation -- 3.8 Peripheral and Central Sensitization -- 3.9 The Brain -- 3.10 Summary -- References -- Chapter 4 The Role of Inflammation in Vulvodynia -- 4.1 Introduction -- 4.2 A Review of the Evolving Research into the Inflammatory Pathogenesis of Vulvodynia -- 4.2.1 Histological Evidence of Inflammation in Vulvodynia -- 4.2.2 Innate Immunity, Inflammation, and Development of Vulvodynia Pain -- 4.2.3 Hormonal Contribution to Inflammation and Vulvodynia -- 4.2.4 Studies of Systemic Immune Challenges and Associated Proinflammatory Genetics -- 4.2.5 Studies of Blood Flow Change (Rubor) as a Hallmark of Inflammation -- 4.2.6 Preclinical Models Connect a Preclinical Genital Pain Disorder with Inflammation -- 4.3 A Theoretical Model of Vulvodynia Etiopathogenesis -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 5 Neuroproliferative Processes in Vulvodynia -- 5.1 Introduction -- 5.2 Mast Cells and Hyperinnervation -- 5.3 Genetic Predisposition to Neuroproliferation and Allodynia -- 5.4 Animal Models Support the Evidence of Neuroproliferation in Vestibulodynia -- 5.5 Discussion -- References -- Chapter 6 Pelvic Floor Muscle Dysfunction and Structural Processes in Vulvodynia -- 6.1 Introduction -- 6.2 Anatomy and Function of the Pelvis -- 6.3 Disorders of the Symphysis Pubis -- 6.4 Hip Disorders -- 6.5 Pelvic Obliquity -- 6.6 Sacroiliac Joint Disorders -- 6.7 Coccydynia -- 6.8 Abdominal Wall/Anterior Pelvic Pain -- 6.9 Piriformis/Buttock Pain -- 6.10 Lumbar Spine Disorders -- 6.11 Pudendal Neuralgia -- 6.12 Conclusion -- References -- Chapter 7 Hormonal Causes of Dyspareunia -- 7.1 Introduction -- 7.2 Combined Hormonal Contraceptives -- 7.2.1 Mechanism of Action -- 7.2.2 CHC-induced Morphological Changes to the Vulva -- 7.2.3 CHC-induced Changes in Arousal/Lubrication -- 7.2.4 CHC and Vestibulodynia -- 7.2.5 Treatment of Vestibulodynia Caused by CHCs -- 7.3 Spironolactone -- 7.4 Hormonal Therapy for Breast Cancer -- 7.4.1 Tamoxifen -- References -- Chapter 8 Genetic Factors in Vulvodynia -- References -- Chapter 9 Central Factors in Vulvodynia -- 9.1 Introduction -- 9.2 Central Mechanisms in Vulvodynia -- 9.2.1 Quantitative Sensory Testing -- 9.2.2 Central Imaging Studies -- 9.2.3 Autonomic Function -- 9.2.4 What Are the Clinical Implications? -- References -- Chapter 10 Comorbidities of Vulvodynia -- 10.1 Introduction -- 10.2 Comorbid Conditions -- 10.2.1 Fibromyalgia -- 10.2.2 Interstitial Cystitis/Bladder Pain Syndrome -- 10.2.3 Irritable Bowel Syndrome -- 10.2.4 Headaches and Orofacial Pain Disorders -- 10.3 Mechanism of Comorbidity -- 10.4 Implications for Treatment and Effect on Outcomes -- 10.4.1 Management -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 11 Psychosocial Factors in Vulvodynia -- 11.1 Introduction -- 11.2 Preview of our Interpersonal Emotion Regulation Model -- 11.3 Distal and Proximal Interpersonal Factors in Vulvodynia -- 11.3.1 Distal Interpersonal Factors in Vulvodynia -- 11.3.2 Proximal Interpersonal Factors in Vulvodynia -- 11.4 Conclusions -- References -- Chapter 12 Pain Assessment in Vulvodynia: Self-report Measures -- 12.1 Introduction -- 12.2 Setting Up a Validating Context -- 12.3 General Information to Gather -- 12.4 Pain-specific Assessment -- 12.4.1 Pain Intensity -- 12.4.2 Pain Quality and Affect -- 12.4.3 Temporal Pattern -- 12.4.4 Cognitive and Emotional Responses to the Pain -- 12.4.5 Functional Measures -- 12.5 Conclusions -- References -- Chapter 13 Pain Assessment in Vulvodynia: Objective Measures -- 13.1 Introduction -- 13.2 Objective Measures Focusing on the Vestibule -- 13.2.1 Cotton-swab Test -- 13.2.2 Vulvalgesiometer -- 13.2.3 Tampon Test -- 13.2.4 Quantitative Sensory Testing -- 13.3 Objective Measures Focusing on the Pelvic Floor -- 13.3.1 Manual Palpation -- 13.4 Tools and Instruments to Assess PFM Involvement -- 13.4.1 Electromyography -- 13.4.2 Manometry -- 13.4.3 Dynamometry -- 13.4.4 Myotonometry -- 13.4.5 Ultrasound Imaging -- 13.5 Conclusions -- References -- Chapter 14 An Overview of the Evaluation of Dyspareunia, Vulvovaginal Pain, and Pelvic Pain -- 14.1 Introduction -- 14.2 Evaluation -- 14.2.1 Medical History -- 14.2.2 Psychosocial History -- 14.2.3 Medication History -- 14.2.4 Additional Aspects of Patients' Medical History -- 14.2.5 Physical Examination -- 14.2.6 Testing -- 14.3 Summary -- References -- Chapter 15 Vulvoscopic Evaluation of Vulvodynia -- 15.1 Introduction -- 15.2 Equipment and Setup -- 15.3 Steps of Vulvoscopy/ Vulvoscopy Standard Operating Procedure -- 15.3.1 Vulvoscopy Standard Operating Procedure. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 15.3.2 Pubic Hair -- 15.3.3 Labia Majora -- 15.3.4 Interlabial Sulcus -- 15.3.5 Labia Minora -- 15.3.6 Clitoris -- 15.3.7 Urethral Meatus -- 15.3.8 Vulvar Vestibule -- 15.3.9 Vagina -- 15.4 Use of Acetic Acid -- 15.5 Research and Future Directions -- 15.6 Summary of Vulvoscopy Steps -- References -- Chapter 16 Pelvic Floor Assessment of Vulvodynia -- 16.1 Introduction -- 16.2 Pelvic Floor Anatomy and Physiology -- 16.3 Patient History -- 16.4 Physical Therapy Examination -- 16.4.1 Neurological Testing -- 16.4.2 General Considerations for the Transvaginal Pelvic Floor Examination -- 16.4.3 Transvaginal Pelvic Floor Examination -- 16.5 Physical Therapy Assessment and Treatment Plan -- 16.6 Assessment and Treatment -- 16.7 Evidence for Physical Therapy Treatment -- 16.8 Conclusion -- References -- Chapter 17 Psychosocial Assessment of Vulvodynia -- 17.1 Introduction -- 17.2 Consequences of Vulvodynia or Associated Difficulties -- 17.3 Overview of Presenting Problem -- 17.4 Cognitive, Affective, Behavioral, and Relational Contributors -- 17.4.1 Cognitive and Behavioral -- 17.4.2 Affective -- 17.4.3 Relational -- 17.5 Exploring the Past: Childhood Victimization -- 17.6 Conclusions -- References -- Chapter 18 Neurological Assessment in Genito-pelvic Pain -- 18.1 Introduction -- 18.2 Vibration Perception Threshold Testing -- 18.3 Cold and Warm Temperature Perception Threshold Testing -- 18.4 Sacral Dermatome Testing -- 18.5 Bulbocavernosus Reflex Latency Testing -- 18.6 Pathologies of Genito-pelvic Pain -- References -- Chapter 19 Diagnostic and Treatment Algorithm for Women with Vulvodynia and Sexual Pain Disorders -- 19.1 Introduction -- 19.2 The Diagnostic Algorithm -- Chapter 20 Medical Treatment of Inflammatory-associated Provoked Vestibulodynia -- 20.1 Introduction -- 20.2 Patient History and Clinical Presentation. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 20.3 Inflammation: Pathophysiology and Basic Science Research -- 20.4 Treatment of IPVD -- 20.5 Conclusion -- References -- Chapter 21 Treatment of Neuroproliferative-associated Provoked Vestibulodynia with Topical Medications -- 21.1 Introduction -- 21.2 Lidocaine -- 21.3 Amitriptyline -- 21.4 Gabapentin -- 21.5 Capsaicin -- 21.6 Ketamine -- 21.7 Treatment Recommendations -- 21.8 Conclusions -- References -- Chapter 22 Hormonal Factors in Women's Sexual Pain Disorders -- 22.1 Introduction -- 22.2 Sex Steroid Androgens and Estrogens: Physiology -- 22.3 Menopause: Androgen and Estrogen Deficiency -- 22.4 Premenopause and Androgen Deficiency -- 22.5 Hormonally Mediated Vestibulodynia -- 22.6 Conclusion -- References -- Chapter 23 Physical Therapy Treatment of Pelvic Floor Dysfunction -- 23.1 Introduction -- 23.2 Manual Therapy Techniques -- 23.2.1 Overview -- 23.2.2 Myofascial Release -- 23.2.3 Visceral Manipulation -- 23.2.4 Neural Mobilization -- 23.2.5 Joint Mobilization -- 23.3 Therapeutic Exercise -- 23.3.1 Spinal ("Core") Stabilization -- 23.3.2 Pelvic Floor Muscle Retraining -- 23.3.3 Behavioral Therapies -- 23.3.4 Additional Modalities -- 23.4 Conclusion -- References -- Chapter 24 Treatment of Vulvodynia with Pelvic Floor Muscle Relaxants/Injections -- 24.1 Introduction -- 24.2 Trigger Point Injections -- 24.3 Pelvic Nerve Blocks -- 24.3.1 Pudendal Nerve -- 24.3.2 Ilioinguinal and Genitofemoral Nerves -- 24.3.3 Ganglion Impar -- 24.4 Injection Agents -- 24.4.1 Interferon -- 24.4.2 Corticosteroid Injections -- 24.4.3 Botulinum Toxin -- 24.4.4 Muscle Relaxants -- 24.5 Conclusion -- References -- Chapter 25 Psychosocial Treatments for Vulvodynia -- 25.1 Introduction -- 25.2 Psychosocial Treatments: Empirical Evidence -- 25.3 Therapy Phases and Process -- 25.3.1 Initial Phase: Alliance Building, Psychoeducation, and Goal Formulation. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 25.3.2 Second Phase: Treatment Strategies for Pain and Sexual Dysfunction. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Dyspareunia. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pukall, Caroline F. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Goldstein, Irwin. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Goldstein, Andrew T. |
| Title | Female Sexual Pain Disorders |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2020 |
| International Standard Book Number | 9781119482666 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6317475">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6317475</a> |
| Public note | Click to View |
No items available.